Sino Biopharmaceutical (HKG:1177) obtained marketing approval for its anlotinib hydrochloride capsules in combination with chemotherapy from China's National Medical Products Administration, a Monday Hong Kong bourse filing said.

The approval is for the first-line treatment of patients with locally advanced or metastatic soft tissue sarcoma.